United Health Products, Inc.

UEECdata completeness 75%16 fiscal years on file

Data notes: no data for concept 'pretaxIncome'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$591$37,5002$03$04$04
Net income−$30.5M5−$1.69M6−$2.62M7−$2M8−$2.67M8
Operating cash flow−$828,0799−$619,72010−$2.2M11−$1.19M12−$1.19M12
Capital expenditure$013
Free cash flow (derived)−$828,0799
Total debt
Cash & equivalents$21,79914$13,37714$95,42015$168,88315$65,24915
Diluted shares228.7M230.9M239.1M248.2M257.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.15
your share of equity
Profit it earned you last year
−$0.1
Free cash flow it threw off
Debt you’d be carrying

10 shares is a claim on −$0.15 of net worth that earned you −$0.1 last year.

iii. Is this a good business?
Moat signal · return on equity
avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+12% shares · 5y

Share count is up 12% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001477932-23-001788 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001477932-24-001671 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001477932-25-002110 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001477932-26-002286 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001477932-23-001788 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001477932-24-001671 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001477932-25-002110 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001477932-26-002286 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001477932-23-001788 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001477932-24-001671 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001477932-25-002110 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001477932-26-002286 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-12-31 · accession 0001477932-22-001949 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2021-12-31 · accession 0001477932-23-001788 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-12-31 · accession 0001477932-26-002286 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)